BCL2AETooL
Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Released: August 23, 2024

Expiration: August 22, 2025

Farrukh T. Awan
Farrukh T. Awan, MD, MS, MBA
Courtney DiNardo
Courtney DiNardo, MD, MSCE
Daniel A. Pollyea
Daniel A. Pollyea, MD, MS
Caitlin R. Rausch
Caitlin R. Rausch, PharmD, BCOP

Introduction

An interactive decision support tool designed to help HCPs manage adverse events associated with BCL-2 inhibitors in the setting of hematologic malignancies.

Interactive Decision Support Tool

Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Disclaimer

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on optimal management choices for adverse events associated with BCL-2 inhibitor therapy in AML, CLL, or SLL. The information provided is based on NCCN guideline recommendations, prescribing information for venetoclax, and expert guidance from Farrukh Awan, MD, MS, MBA; Courtney DiNardo, MD, MSCE; Daniel A. Pollyea, MD, MS; and Caitlin R. Rausch, PharmD, BCOP.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content